Oligodendrogliomas frequently, but not always show sensitivity to chemotherapy and recent studies demonstrated that allelic loss of chromosome 1p is highly associated with this chemosensitivity. To gain insight into the molecular mechanism of such dierence, we examined comprehensive gene expression pro®les of 11 oligodendroglial tumors, six with and ®ve without 1pLOH (loss of heterozygosity), and two normal brain tissues using the oligonucleotide microarray (GeneChip). Statistically signi®cant numbers of genes were expressed dierentially between the two genetic subsets. Clustering analysis separated the tumor subsets well. The tumors with 1pLOH had similar expression pro®les to the normal brain for those dierentially expressed genes. Many genes showing higher expression in tumors with 1pLOH were presumed to have functions in nervous tissues. Notably, the majority of the 123 genes showing signi®cant expression reduction in tumors with 1pLOH were either on chromosome 1 (50%) or on 19 (10%), and the average expression reduction ratio was about 50% (0.54+0.13) possibly re¯ecting the chromosomal deletion. Thus, the biological dierence between the genetic subsets of oligodendroglioma was indeed re¯ected to gene expression pro®le, which provided baseline
Introduction
Oligodendrogliomas are a major type of gliomas which constitute approximately 5% of all primary brain tumors or 10 to 25% of all intracranial gliomas (Kleihues and Cavenee, 2000) . One of the important recent ®ndings in neuro-oncology was that those oligodendrogliomas frequently showed remarkable sensitivity to chemotherapy, especially to a regimen using procarbazine, CCNU and vincristine (PCV therapy) (Cairncross and Macdonald, 1988) . However, the response rate to PCV therapy remains 60 ± 80%, and 20 ± 30% of tumors are resistant to chemotherapy and have worse prognosis. Therefore, within this histologically indistinguishable entity, there apparently exist subgroups showing dierent biological behavior. Recent molecular genetic studies on oligodendrogliomas revealed that allelic loss of chromosome 1p, which is found in 60 ± 80% of oligodendrogliomas and often accompanied with allelic loss of 19q (Smith et al., 1999) , was highly associated with the treatment responsiveness and also with a better prognosis (Cairncross et al., 1998; Ino et al., 2001) . Thus, it is now being recognized that loss of chromosome 1p is a marker separating oligodendrogliomas into subgroups showing dierent biological behavior. In addition to its important clinical implications, understanding of the underlying molecular mechanisms of such a dierence may lead to a new treatment strategy for all gliomas. Unfortunately, the putative tumor suppressor genes at chromosomes 1p and 19q, obvious keys to investigate the molecular biologic features of the tumor cells, are yet to be identi®ed despite vigorous investigations. Several attractive candidates on chromosome 1p include TP73 (1p36.3) and CDKN2C (1p32), but neither has been shown to be altered in the majority of oligodendrogliomas (Husemann et al., 1999; Mai et al., 1998) . Although 1p loss is also found in many other neoplasms including neuroblastomas, the search for the suppressor gene in such neoplasms has not been successful either (Ohira et al., 2000; Schwab et al., 1996) . To gain insight into the molecular basis of the biological dierence among oligodendrogliomas, we turned to recently developed oligonucleotide microarray technology. By analysing comprehensive gene expressions, several studies have now shown that the expression pro®les correlated well with the histology and clinical grades in human neoplasms including gliomas (Golub et al., 1999; Huang et al., 2000; Watson et al., 2001) . Therefore, we performed a comparative study of the gene expression pro®les between the genetic subgroups of oligodendrogliomas based on the 1p status.
Results

Genetic alterations in oligodendroglial tumor samples
Of 40 oligodendroglial tumors we could collect, we selected six cases with 1pLOH (loss of heterozygosity) and ®ve cases without 1pLOH from which we could obtain good quality RNA evaluable with the GeneChip system (Aymetrix, Santa Clara, CA, USA). Histological diagnoses and the results of molecular genetic analysis are summarized in Table 1 . There were seven oligodendrogliomas, one oligoastrocytoma and three anaplastic oligodendrogliomas. In all six tumors with 1pLOH, all of the informative 1p markers showed LOH, indicating that deletion involved the whole arm of chromosome 1p (data not shown). Of the six cases with 1pLOH, ®ve cases also had 19qLOH and one case was non-informative on examined 19q markers. None of the six tumors with 1pLOH had TP53 mutation, and three of the ®ve tumors without 1pLOH had TP53 mutation. No case had 10qLOH.
The statistical analysis of genes differentially expressed by 1p status
To select genes that were expressed dierentially by 1p status, we used prediction value (P-value) in neighborhood analysis, which was recently described as useful for extracting genes expressed uniformly high in one group and low in the other (Golub et al., 1999) . We listed a total of 209 genes that had an absolute Pvalue of more than one, of which 86 genes showed higher expression and 123 genes showed lower expression in tumors with 1pLOH. These numbers of the genes were signi®cantly higher than expected in random grouping tested by 1000 times permutation test (P50.01), indicating that these two subgroups indeed have signi®cantly dierent gene expression pro®les. When Mann ± Whitney test with cut-o Pvalues of 0.05 and 0.01 were used, 288 and 123 genes were detected as dierentially expressed by the 1p status, and those numbers were higher than the expected numbers in permutation test which were 115 and 33 in median, respectively. Of the 209 genes selected by prediction value, more than 90% (192 genes) were also included in the 288 genes selected by a P-value of 0.05 by Mann ± Whitney test, indicating the consistency of those two methods in selecting dierentially expressed genes. We used the 209 genes for further analysis.
Clustering analysis was performed to classify all 13 samples using Pearson correlation with these extracted 209 genes (Figure 1 ). The tumor subsets were separated well and the normal brain samples were clustered into the same group with the tumors with 1pLOH. Among the ®ve tumors without 1pLOH, expression pro®les were not markedly dierent between the tumors with and without TP53 mutation in this clustering analysis.
Genes showing higher expression in tumors with 1pLOH
Of the 86 genes selected by P-value, 24 genes whose mean average dierence had more than threefold dierence between the two groups were listed in Table  2 . The average dierences of those genes in normal brain RNA were close to those in tumors with 1pLOH as expected by the clustering analysis. Based on the UniGene on National Center for Biotechnology Information (NCBI), 14 of the 24 genes were predominantly expressed in brain or neural tissues (KIAA0985, RGS7, human clone 23695, INA, KIAA0750, MYT1L, human clone 23560, PTPRN, SLC1A2, HAPIP, SNCB, SNAP25, L1CAM and OLFM1), and were likely to have some function in the nervous system. In the normal brain samples, genes that are predominantly expressed in glial cells such as glial ®brillary acidic protein (GFAP) and myelin basic protein (MBP) were also well expressed, indicating that these samples contained many glial cells. Genes showing lower expression in tumors with 1pLOH and their chromosomal location
Of the 123 genes selected by P-value, 61 genes (50%) were mapped to chromosome 1 (58 to 1p, 1 to 1q, and 2 to 1p or 1q) and 12 genes (10%) were mapped to chromosome 19 (11 to 19q, and 1 to 19p), while 50 genes (41%) were mapped to other chromosomes. When we focused on top 30 genes that had an absolute P-value: prediction value, which re¯ects the dierence between two groups (the details are described in Materials and methods). Expression level of each gene was demonstrated as a mean value and a s.d. of average dierences in each subgroup. Of the 86 genes selected by P-value, 24 genes whose mean average dierence had more than threefold dierence between the tumors with and without 1pLOH are listed. The genes examined by semi-quantitative RT ± PCR are indicated by * P-value of more than 1.5, 83% (25 genes) were mapped to chromosome 1 or 19. Relative expressions of the 73 genes, 61 on chromosome 1 and 12 on chromosome 19, in tumors with 1pLOH compared to tumors without 1pLOH were 0.54+0.13 in average. Of the 123 genes, 16 genes whose mean average dierence had more than threefold dierence between the two groups were listed in Table 3 (whole list of the selected genes would be available on request).
The validation using semi-quantitative RT ± PCR
Of the 24 higher expressed and 16 lower expressed genes in 1pLOH tumors, semi-quantitative RT ± PCR was performed on nine known genes whose dierences were more than fourfold and also more than 40 in mean average dierence between the two groups (indicated by * in Tables 2 and 3 ). The results of RT ± PCR corresponded well to the GeneChip data ( Figure 2 ). The additional tumor samples showed similar expression pattern to the same 1p status cases examined by GeneChip, although there were two cases (case 18 and 19) which showed exceptional expression pattern. Those two cases neither had allelic loss on 1p/ 19q nor had TP53 mutation. The case 19 was rather similar to the 1pLOH tumors. Case 18 showed lower expression in some of the genes that had higher expression in other tumors without 1pLOH.
Expression of genes on chromosome 1p
The relative expressions of the genes on chromosome 1p (n=158) in tumors with 1pLOH against tumors without 1pLOH were arranged on the chromosome map to see their relationship with chromosomal loci (Figure 3) . Genes showing lower expression in tumors with 1pLOH were distributed over the whole chromosome 1p arm. There also were many genes whose expressions were not decreased in 1pLOH tumors, which were also found in various chromosomal loci.
Discussion
Using the oligonucleotide microarray technology, we could identify genes that were dierentially expressed between the subgroups of oligodendroglioma by the 1p status. Results of semi-quantitative RT ± PCR performed on some of the identi®ed genes were concordant with the chip analysis data, con®rming the ®delity of the system in general. Additional oligodendrogliomas studied by RT ± PCR showed similar expression pattern to the GeneChip cases according to their 1p status. Of the ®ve tumors without 1pLOH and without TP53 mutation, however, one additional case was rather similar to the tumors with 1pLOH and another additional case also showed some inconsistency. Such variations of gene expression pattern suggest heterogeneity in tumors without 1pLOH and that more than two subgroups may exist in oligodendroglial tumors, as reported recently (Ino et al., 2001) . The numbers of cases analysed in our study were still limited, and a larger-scale study would enable detailed classi®cation of oligodendroglial tumors based on gene expression pro®les. Nonetheless, our data clearly showed that oligodendrogliomas of dierent genetic subsets indeed had distinct gene expression pattern, and could identify many dierentially expressed genes. Five of 10 cases without 1pLOH had TP53 mutation, and the expression patterns of the genes examined by RT ± PCR were not signi®cantly dierent between tumors with and without TP53 mutation. There was no apparent dierence in the expression pattern of the 209 genes among ®ve tumors without genes whose mean average dierence had more than threefold dierence between the tumors with and without 1pLOH are listed. The genes examined by semi-quantitative RT ± PCR are indicated by * 1pLOH examined by GeneChip, regardless of the TP53 mutation status (data not shown). Therefore, the listed genes were most likely extracted by the status of 1pLOH than that of TP53. Of the genes showing higher expression in tumors with 1pLOH (see Table 2 ), we noticed several genes that were expressed predominantly in normal brain or neural tissue, indicating that those genes are functional in the normal nervous system. Contamination of normal tissue cells was not likely, because allelic losses observed on the microsatellite analysis were almost complete in all cases, indicating that the examined Figure 2 Results of semi-quantitative RT ± PCR. Eleven tumors (#1 ± 11) used in the GeneChip experiments (printed in boldface), nine additional tumors (#12 ± 20), and two normal brain tissues (#21, 22) were analysed. The upper six genes and the middle three genes showed higher and lower expression in 1pLOH tumors in the GeneChip experiment, respectively. GAPDH was used as a control Figure 3 The relative expressions of the genes on chromosome 1p. Horizontal-axis represents the location of the examined 158 genes demonstrated from telomere (left) to centromere (right). Vertical-axis represents relative expressions with error bar, dividing the mean expressions (average dierence) of tumors with 1pLOH by those of tumors without 1pLOH. The value beyond 1.7 is not shown in this ®gure tissues consisted mostly of tumor cells. For example, MYT1L encodes a zinc ®nger protein which plays a role in the development of neurons in the central nervous system (Kim et al., 1997) , and PTPRN, which had especially similar expression pattern to MYT1L in the RT ± PCR analysis, is implicated in neuroendocrine secretory processes. SNCB plays a role in neuronal plasticity, SLC1A2 is a glial high anity glutamate transporter, and HAPIP is also abundantly expressed in the neural tissues. L1CAM is an axonal glycoprotein involved in neuronal migration and dierentiation (Kenwrick et al., 2000) . In combination with the results of clustering, these data may suggest that tumors without 1pLOH are more distant from normal brain, possibly re¯ecting their dierentiation status.
Analysis on the dierentially expressed genes provided potentially interesting information on their chromosomal locations. Of the top 123 genes whose expressions were most signi®cantly decreased in tumors with 1pLOH, nearly 60% were located either on chromosome 1 or chromosome 19, with the ratio of expression levels to tumors without 1pLOH around 50%. It was reported that nearly all oligodendrogliomas with 1p and 19q LOH lose the entire arm of 1p and 19q (Bigner et al., 1999; Nigro et al., 2001; Smith et al., 1999) , which was also con®rmed by our microsatellite analysis on 1p. Therefore, reduced expression of genes in a wide range of 1p is likely to be a consequence of losing one copy of each gene. On the other hand, some genes on chromosome 1p had higher expressions in tumors with 1pLOH, suggesting that the expression regulations of those genes were not simply dependent on the copy number. In a few genes such as COL11A1 and RBBP4, the relative expressions were remarkably low probably because of their overexpression in tumors without 1pLOH, rather than their expression reduction in 1p losing tumors (see Table 3 ). Despite the rather comprehensive expression analysis, we still could not pinpoint a particular gene that would aect the chemosensitivity of oligodendrogliomas. None of the genes previously suggested to be related with chemosensitivity, such as O 6 -methylguanine-DNA methyltransferase (MGMT), multidrug resistance 1 (MDR1), multidrug resistance-associated protein (MRP), glutathione S-transpherase pi, metallothionein and topoisomerase IIa (Nutt et al., 2000; Tanaka et al., 2000) , were detected as dierentially expressed genes in our study. On the other hand, we showed that signi®cant numbers of genes were dierentially expressed between oligodendroglioma subsets, including expression reduction of numerous genes in the chromosome 1p. An interesting question is whether about 50% reduction of such numerous genes in the same chromosomal region could have any biological eect on tumorigenesis or chemosensitivity. Recent studies showed that loss of one copy of a gene and subsequent reduction of its expression level is possibly related to tumorigenesis, a phenomenon called haplo-insuciency (Fero et al., 1998; Gutmann et al., 1999) . Whether similar phenomenon underlies the biological features of oligodendroglioma remains to be investigated.
From a technological point of view, it could be an important observation that the oligonucleotide microarray may be quantitative enough to detect expression reduction caused by the allelic loss in numerous genes. cDNA microarray and serial analysis of gene expression (SAGE) have been tried with some success to detect increase or decrease of expressions of certain genes which were altered by gene ampli®cations or deletions (Caron et al., 2001; Pollack et al., 1999) . Our data indicated that oligonucleotide microarray would be a good system to identify such genes.
In summary, we showed that genetic subsets in oligodendrogliomas by 1p status were re¯ected in gene expression pro®le. Some of the interesting genes dierentially expressed included genes implicated in the function of nervous tissues, genes on chromosome 1p and 19q. Molecular mechanism of chemosensitivity and chemoresistance may well be represented by those dierentially expressed genes, and our data would serve as good baseline data for the future studies to solve that clinically important question.
Materials and methods
Sample preparation
Tumor samples obtained at surgery were snap frozen in liquid nitrogen and stored at 7808C until use. Histological diagnosis was made on formalin-®xed paran-embedded tissues processed separately. To minimize the notorious variability of the histological diagnosis in oligodendroglial tumors, the histology slides were reviewed by four independent neuropathologists to make consensus diagnoses following the WHO classi®cation (Kleihues and Cavenee, 2000) . Paired blood samples were obtained after written informed consents, and were subjected to DNA extraction for the microsatellite analysis. Of 40 oligodendroglial tumors, six tumors with 1pLOH and ®ve without 1pLOH were selected for expression pro®ling using GeneChip system (Aymetrix). Total RNA from normal whole brain was purchased from two dierent providers (Clontech, Palo Alto, CA, USA and Life Technologies, Inc., Rockville, MD, USA), which were used to see the expression pro®le of the normal neurons and glial cells.
Genetic analysis
LOH assay on chromosomes 1p, 19q and 10q to detect allelic losses were performed using Genetic Analyzer 310 (Applied Biosystems, Foster City, CA, USA) as previously described. The following microsatellite markers located at the commonly deleted in gliomas were used: D1S244, D1S2734, and D1S402 for 1p (1p36), D19S112, D19S596, D19S412 and D19S219 for 19q (19q13) , D10S1744, D10S1680 and D10S583 for 10q (10q22-23) (Ueki et al., 2000) . For tumors with 1pLOH, four additional 1p markers were further examined to see the range of the deletion: D1S1166 (1p13), D1S495 (1p22), D1S2835 (1p32) and D1S2657 (1p34). The SSCP assay for exons 5 to 8 of TP53 was performed using previously published primer pairs (Fults et al., 1992) , again using Genetic Analyzer 310. Exons showing migration shift were PCR ampli®ed again and were directly sequenced using BigDye Terminator Kit (Applied Biosystems) following the manufacturer's protocol. Established comparative multiplex PCR assays were used to detect homozygous deletion of CDKN2A (Ueki et al., 1996) . For RNA extraction, the frozen tumor sample was homogenized in Isogen (Nippon Gene, Osaka, Japan) and total RNA was isolated following manufacturer's instructions.
Gene Chip experiment
Five mg of total RNA from each sample were used to synthesize biotin-labeled cRNA, which was then hybridized to the high-density oligonucleotide array (GeneChip Human U95A array; Aymetrix) following the previously published protocol with minor modi®cations (Ishii et al., 2000) . Arrays contain probe sets for approximately 12 626 human genes and ESTs, which were selected from Build 95 of the UniGene Database (derived form GenBank 113, dbEST/10-02-99). After washing, arrays were stained with streptavidinphycoerythrin (Molecular Probes, Inc., Eugene, OR, USA) and analysed by a Hewlett-Packard Scanner to collect primary data. The GeneChip 3.3 software (Aymetrix) was used to calculate the average dierence for each gene probe on the array, which was shown as an intensity value of gene expression de®ned by Aymetrix using their algorithm. The average dierence has been shown to quantitatively re¯ect the abundance of a particular mRNA molecule in a population (Ishii et al., 2000; Lockhart et al., 1996) . To allow comparison among multiple arrays, the average dierences were normalized for each array by assigning the average of overall average dierence values to be 100. A value of two was assigned to every average dierence below two. Of the total 12 626 probe sets represented on the array, control probes and genes scored as absent (not detected) by the expression algorithm in GeneChip software (Aymetrix) or less than 100 in all 13 samples were excluded from the analysis because of low con®dence of scarcely expressed genes, and 5668 probe sets were left.
Selection of differentially expressed genes
For the selection of dierentially expressed genes by 1p status, we used prediction value (P-value) which re¯ects the dierence between two groups, given by (m17m2)/(s1+s2) when (m1, s1) and (m2, s2) denote the means and standard deviations of the log of the expression level of gene for the sample in group 1 and group 2, respectively (Golub et al., 1999) . Pre-®ltering was applied to select probe sets whose maximum and minimum average dierence among 11 tumor samples diered by more than 100, and had more than twofold dierence. For the remaining 3875 probe sets, the prediction values were calculated. We also used Mann ± Whitney test, which measures whether the distribution of gene expression level between two groups is overlapped.
Clustering analysis
The expression patterns of samples were statistically analysed using GeneSpring 4.0 software (Silicon Genetics, Redwood City, CA, USA). Average dierences were converted into logarithm, and hierarchical clustering was carried out using Pearson correlation coecient of 0.8 (Eisen et al., 1998) .
Semi-quantitative RT ± PCR
Semi-quantitative RT ± PCR was performed using 13 samples used for GeneChip analysis and additional nine oligodendroglial tumors. Of the nine additional cases, four cases had combined 1p and 19q LOH, while ®ve cases had neither genetic alteration. Two of the ®ve additional cases without 1pLOH had TP53 mutation. cDNA was synthesized with oligo-dT primer from 2 mg total RNA, using SuperScript Preampli®cation System (Life Technologies, Inc.). The concentration of the cDNA was equalized using the GAPDH gene expression as a control. PCR was then performed with 2 ml of cDNA for 31 ± 37 cycles, consisted of 30 s of denaturing at 948C, 30 s of annealing at 63 ± 708C and 1 min of extension at 728C. The primer sets used are listed in Table 4 . PCR products were separated by electrophoresis on 1.5% agarose gels and were visualized with ethidium bromide staining. Numbers of PCR cycles were optimized to ensure product intensity within the linear phase of ampli®cation. For each primer set, the amplicon was sequenced after subcloned into pGEM-T Easy vector (Promega, Madison, WI, USA) to con®rm that the correct target gene was ampli®ed.
Identification of gene location
Chromosomal loci of the genes were identi®ed using the locus information from the web sites of GenBank, UniGene and LocusLink on NCBI, by referring to the corresponding GenBank accession number of each probe set.
Detailed chromosomal locations of 950 genes mapped on 1p were obtained from the web site of Map Viewer (Homo sapiens build 26) on NCBI, in which the gene locations are shown by distances from the telomere of the short arm. These 950 genes were matched to the probe sets on Human U95A array by referring to the LocusLink ID, UniGene ID and GenBank accession number, which identi®ed 502 probe sets represented on U95A array. Genes with expressions (average dierence) scored as absent or less than 100 in average of 11 tumors were excluded because of low con®dence in evaluating genes with low expression. For the 158 genes remaining, we calculated relative expressions by dividing the mean expressions in tumors with 1pLOH by those in tumors without 1pLOH, which were then arranged on the chromosome map. 
